4.7 Review

The role of surface molecule CD229 in Multiple Myeloma

期刊

CLINICAL IMMUNOLOGY
卷 204, 期 -, 页码 69-73

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2018.10.006

关键词

Multiple Myeloma; CD229; SLAMF3; SLAM family receptors; Diagnostic markers; Immunotherapy; Monoclonal antibody; CAR T cells

向作者/读者索取更多资源

The outcome of Multiple Myeloma (MM) patients has dramatically improved, however, most patients will still succumb to their disease. Additional therapeutic options are urgently needed and novel immunotherapies are enormously promising in the therapeutic armamentarium against MM. The first step in the development of any immunotherapy needs to be the identification of an appropriate target structure. In this review we present the current knowledge on surface molecule CD229, a member of the Signaling Lymphocyte Activation (SLAM) family of immune receptors. We believe that based on its characteristics, including (1) strong and homogenous expression on all myeloma cells, (2) expression on myeloma precursors, (3) absence from most normal tissues, (4) a central function in the biology of MM, CD229 (SLAMF3) represents a promising target for anti-MM immunotherapies. The introduction of novel anti-CD229 approaches into the clinic will hopefully lead to more durable responses, or maybe even cures, in MM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据